On March 31, 2025, BiomX Inc. announced positive results from its Phase 2 Trial of BX211 for treating Diabetic Foot Osteomyelitis, showing significant improvements in ulcer healing compared to placebo. The trial involved 41 patients and demonstrated safety and efficacy with a notable reduction in ulcer size and depth.